Primary neoplasms of the small intestine

Zollinger, Robert M.; Sternfeld, William C.; Schreiber, Helmut

doi:10.1016/0002-9610(86)90035-8

Cited by 120 publications

(85 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ileal tumours had the highest survival, followed by those of the jejunum and duodenum. Survival has not been shown to vary with subsite in small case series from single institutions (Zollinger, 1986;Cunningham et al, 1997;Ojha et al, 2000). Other studies (Ashley and Wells, 1988;Frost et al, 1994) have shown slightly more favourable prognosis for duodenal adenocarcinomas.…”

Section: Discussionmentioning

confidence: 99%

Survival trends for small intestinal cancer in England and Wales, 1971–1990: national population-based study

Pashayan¹,

Lepage

Rachet

et al. 2006

Br J Cancer

View full text Add to dashboard Cite

This population-based study examines prognostic factors and survival trends among adults (15 -99 years) diagnosed with small intestinal cancer in England and Wales during 1971 -1990 and followed up to 1995. During this period, the 1-and 5-year agestandardised relative survival rates for small intestinal cancers combined were 42% and 23%, respectively. Duodenal tumours, adenocarcinomas, men, patients with advanced age and the most deprived patients had the poorest prognosis. For all small bowel tumours combined, the excess risk of death fell significantly by 6 -9% every 4 years over the 20-year period (adjusted excess hazard ratio (EHR) 0.91 at 1 year after diagnosis, 0.94 at 5 years). For duodenal tumours, the EHR fell by about 14% (95% CI 5 -22%) every 4 years between 1979 and 1990, and a similar trend for jejunal tumours was of borderline significance. Further population-based investigations linking survival data to individual data on diagnostic methods and types of treatment are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival trends for small intestinal cancer in England and Wales, 1971–1990: national population-based study

Pashayan¹,

Lepage

Rachet

et al. 2006

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…When surgery, chemotherapy and radiotherapy were the only options for the treatment of metastatic small intestinal NETs, the prognosis was mediocre and overall 5-year survival rate was approximately 50-60% for all stages combined (Barclay & Schapira 1983, Zollinger 1986. Also patients with a functioning NET had a shorter median survival.…”

Section: Serotonin and The Carcinoid Syndromementioning

confidence: 99%

Effect of hormone secretory syndromes on neuroendocrine tumor prognosis

Zandee

Kamp

Adrichem

et al. 2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

The treatment of hormone hypersecretory syndromes caused by neuroendocrine tumors (NETs) can be a major challenge. NETs originating from the small intestine often secrete serotonin causing flushing, diarrhea and valve fibrosis, leading to dehydration or heart failure in severe cases. NETs from the pancreas can secrete a wider variety of hormones, like insulin, glucagon and gastrin leading to distinct clinical syndromes. Historically mortality in patients with functioning NETs was high due to the complications caused by the hypersecretion of hormones. This has been reduced with several drugs: protonpump inhibitors decrease acid secretion caused by gastrinomas. Somatostatin analogs can inhibit the secretion of multiple hormones and these are now the cornerstone for treating patients with a gastroenteropancreatic NET. However, peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs and everolimus can also decrease symptoms of hypersecretion and increase progression-free survival. Several factors affect the survival in patients with a functioning NET. Complications of hypersecretion negatively impact survival; however, secretion of hormones is also often a sign of a well-differentiated NET and due to the symptoms, functioning NETs can be detected in an earlier stage suggesting a positive effect on prognosis. The effect on survival is also dependent on the type of hormone being secreted. This review aims to study the effect of hormone secretion on the prognosis of NETs with the contemporary treatments options available today.

show abstract

“…La mayoría de los tumores benignos de ID son asintomáticos y diagnosticados en forma incidental, siendo los más comunes: adenoma, tumores estromales gastrointestinales benignos, leiomioma, lipoma, hemangiomas y pólipos, estos últimos pueden ser secundarios a un síndrome de Peutz-Jeghers, enfermedad que se caracteriza por pigmentación mucocutánea y múltiples pólipos hamartomatosos en todo el tracto gastrointestinal, de predominio en el ID (1,2,(4)(5)(6)(7) . Existen diversos métodos para la evaluación del ID, que incluyen estudios baritados, tomografía computada (TC), resonancia magnética (RM), enteroscopía y la cápsula endoscópica.…”

Section: Gastrointestinalunclassified

“…Los tumores de intestino delgado (ID) son raros, representando aproximadamente 3-6% de las neoplasias del tubo digestivo; en pacientes sintomáticos hasta un 60% de los casos son malignos (1,2) . Generalmente tienen una presentación clínica inespecí-fica, similar a otros procesos que afectan al tracto gastrointestinal, por lo que su diagnóstico es tardío y difícil.…”

Section: Introductionunclassified

Utilidad De La Enteroclisis Por Tomografia Computada (E-Tc) en La Detección De Tumores De Intestino Delgado

2008

Rev. chil. radiol.

View full text Add to dashboard Cite

Small bowel neoplasms are rare, accounting for approximately 3-6% of all primary malignancies of the gastrointestinal tract. MDCT-E is an imaging modality that combines the advantages of enteroclysis and helical CT, allowing the detection of small bowel diseases wherever they are located (intraluminal, intramural, or extramural). The aim of our study was to assess the reliability of MDCT-E IntroducciónLos tumores de intestino delgado (ID) son raros, representando aproximadamente 3-6% de las neoplasias del tubo digestivo; en pacientes sintomáticos hasta un 60% de los casos son malignos (1,2) . Generalmente tienen una presentación clínica inespecí-fica, similar a otros procesos que afectan al tracto gastrointestinal, por lo que su diagnóstico es tardío y difícil. En la mayoría de los casos son asintomáticos hasta etapas avanzadas de la enfermedad. Cuando presentan síntomas, los más comunes son: dolor abdominal, pérdida de peso, naúseas, vómitos, diarrea, hemorragia digestiva y obstrucción intestinal, que en general se relacionan con el tamaño tumoral y localización en el ID (3) . Los tumores benignos y malignos del ID pueden tener origen en todos los componentes histológicos que forman el intestino incluyendo: tejido epitelial, tejido linfoide, vasos, nervios y músculo (4) .Besa C. y cols. Utilidad de la enteroclisis por tomografía computada (E-TC) en la detección de tumores de intestino delgado. Rev Chil Radiol 2008; 14: 211-218.

show abstract

Primary neoplasms of the small intestine

Cited by 120 publications

References 13 publications

Survival trends for small intestinal cancer in England and Wales, 1971–1990: national population-based study

Survival trends for small intestinal cancer in England and Wales, 1971–1990: national population-based study

Effect of hormone secretory syndromes on neuroendocrine tumor prognosis

Utilidad De La Enteroclisis Por Tomografia Computada (E-Tc) en La Detección De Tumores De Intestino Delgado

Contact Info

Product

Resources

About